Analysts’ Weekly Ratings Updates for Cogent Biosciences (COGT)

Cogent Biosciences (NASDAQ: COGT) recently received a number of ratings updates from brokerages and research firms:

• 11/14/2024 – Cogent Biosciences had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an “overweight” rating on the stock.
• 11/13/2024 – Cogent Biosciences had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a “buy” rating on the stock.
• 11/12/2024 – Cogent Biosciences had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
• 11/4/2024 – Cogent Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
• 10/24/2024 – Cogent Biosciences had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
• 9/24/2024 – Cogent Biosciences had its price target raised by analysts at Citigroup Inc. from $13.00 to $15.00. They now have a “buy” rating on the stock.

Cogent Biosciences Stock Performance

Shares of NASDAQ COGT traded up $0.15 during midday trading on Friday, hitting $9.13. 644,946 shares of the stock traded hands, compared to its average volume of 1,428,004. Cogent Biosciences, Inc. has a one year low of $3.67 and a one year high of $12.61. The firm has a market capitalization of $1.01 billion, a P/E ratio of -3.68 and a beta of 1.72. The firm has a 50-day moving average of $10.83 and a two-hundred day moving average of $9.61.

Cogent Biosciences (NASDAQ:COGT) last announced its earnings results on Tuesday, November 12th. The technology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). During the same quarter last year, the firm earned ($0.64) EPS. Equities analysts forecast that Cogent Biosciences, Inc. will post -2.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cogent Biosciences

A number of hedge funds have recently made changes to their positions in the business. Values First Advisors Inc. bought a new stake in Cogent Biosciences in the 3rd quarter worth approximately $32,000. Mirae Asset Global Investments Co. Ltd. increased its position in Cogent Biosciences by 38.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,959 shares of the technology company’s stock worth $43,000 after purchasing an additional 1,104 shares during the last quarter. nVerses Capital LLC purchased a new stake in Cogent Biosciences during the third quarter valued at $76,000. Russell Investments Group Ltd. lifted its position in Cogent Biosciences by 234.5% during the first quarter. Russell Investments Group Ltd. now owns 10,014 shares of the technology company’s stock valued at $67,000 after purchasing an additional 7,020 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new position in shares of Cogent Biosciences in the 3rd quarter worth $113,000.

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.